ES2139552T1 - Moduladores de la transcripcion regulado por tetraciclinas. - Google Patents

Moduladores de la transcripcion regulado por tetraciclinas.

Info

Publication number
ES2139552T1
ES2139552T1 ES95926605T ES95926605T ES2139552T1 ES 2139552 T1 ES2139552 T1 ES 2139552T1 ES 95926605 T ES95926605 T ES 95926605T ES 95926605 T ES95926605 T ES 95926605T ES 2139552 T1 ES2139552 T1 ES 2139552T1
Authority
ES
Spain
Prior art keywords
tet
linked
tetracicline
analogue
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES95926605T
Other languages
English (en)
Other versions
ES2139552T3 (es
Inventor
Hermann Bujard
Manfred Gossen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/275,876 external-priority patent/US5654168A/en
Priority claimed from US08/383,754 external-priority patent/US5789156A/en
Application filed by Knoll GmbH, BASF SE filed Critical Knoll GmbH
Publication of ES2139552T1 publication Critical patent/ES2139552T1/es
Application granted granted Critical
Publication of ES2139552T3 publication Critical patent/ES2139552T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE PRESENTAN MOLECULAS Y PROTEINAS DE ACIDOS NUCLEICOS UTILES PARA REGULAR LA EXPRESION DE GENES EN CELULAS EUCARIOTICAS Y ORGANISMOS. EN LA INVENCION SE PRESENTA UNA PROTEINA DE FUSION ACTIVADORA TRANSCRIPCIONAL QUE SE ENLAZA A SECUENCIAS OPERADORAS TET Y ESTIMULA LA TRANSCRIPCION DE UN GEN ENLAZADO A UN OPERADOR TET EN PRESENCIA, PERO NO EN AUSENCIA, DE TETRACICLINA (O ANALOGO DE LA MISMA). EN LA INVENCION TAMBIEN SE PRESENTAN PROTEINAS DE FUSION INHIBIDORAS TRANSCRIPCIONALES QUE INHIBEN LA TRANSCRIPCION DE UN GEN ENLAZADO A UN OPERADOR TET DE FORMA CONTROLADA. EN UN ASPECTO DE LA INVENCION, LA PROTEINA DE FUSION INHIBIDORA SE ENLAZA A SECUENCIAS DE OPERADORES TET EN AUSENCIA, PERO NO EN PRESENCIA, DE TETRACICLINA (O ANALOGO DE LA MISMA). EN OTRO ASPECTO DE LA INVENCION, LA PROTEINA DE FUSION INHIBIDORA SE ENLAZA A SECUENCIAS DE OPERADORES TET EN PRESENCIA, PERO NO EN AUSENCIA, DE TETRACICLINA (O ANALOGO DE LA MISMA). LAS PROTEINAS DE FUSION ACTIVADORAS E INHIBIDORAS TRANSCRIPCIONALES DELA INVENCION SE PUEDEN UTILIZAR COMBINADAS PARA REGULAR LA EXPRESION DE UNO O DE MULTIPLES GENES ENLAZADOS A OPERADORES TET. TAMBIEN SE PRESENTAN NUEVAS UNIDADES DE TRANSCRIPCION QUE CONTIENEN OPERADORES TET QUE PERMITEN LA EXPRESION REGULADA POR TETRACICLINA COORDINADA O INDEPENDIENTE DE DOS O MAS GENES MEDIANTE LOS MODULADORES TRANSCRIPCIONALES DE LA INVENCION. TAMBIEN SE PRESENTAN EN LA INVENCION LOS KITS QUE INCLUYEN LOS COMPONENTES DEL SISTEMA REGULADOR.
ES95926605T 1994-07-01 1995-06-29 Moduladores transcripcionales regulados por tetraciclina. Expired - Lifetime ES2139552T3 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US27063794A 1994-07-01 1994-07-01
US270637 1994-07-01
US08/275,876 US5654168A (en) 1994-07-01 1994-07-15 Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US275876 1994-07-15
US08/383,754 US5789156A (en) 1993-06-14 1995-02-03 Tetracycline-regulated transcriptional inhibitors
US383754 1995-02-03
US486814 1995-06-07
US08/486,814 US5866755A (en) 1993-06-14 1995-06-07 Animals transgenic for a tetracycline-regulated transcriptional inhibitor

Publications (2)

Publication Number Publication Date
ES2139552T1 true ES2139552T1 (es) 2000-02-16
ES2139552T3 ES2139552T3 (es) 2006-04-16

Family

ID=27501005

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95926605T Expired - Lifetime ES2139552T3 (es) 1994-07-01 1995-06-29 Moduladores transcripcionales regulados por tetraciclina.

Country Status (13)

Country Link
US (2) US5866755A (es)
EP (2) EP0804565B1 (es)
JP (3) JP4054058B2 (es)
CN (2) CN1167504A (es)
AT (1) ATE305034T1 (es)
AU (1) AU3092395A (es)
CA (1) CA2193122C (es)
DE (2) DE69534472T2 (es)
DK (1) DK0804565T3 (es)
ES (1) ES2139552T3 (es)
FI (1) FI965287A7 (es)
NO (1) NO315375B1 (es)
WO (1) WO1996001313A1 (es)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
WO1994029442A2 (en) 1993-06-14 1994-12-22 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5912411A (en) * 1993-06-14 1999-06-15 University Of Heidelberg Mice transgenic for a tetracycline-inducible transcriptional activator
US5888981A (en) 1993-06-14 1999-03-30 Basf Aktiengesellschaft Methods for regulating gene expression
US5859310A (en) 1993-06-14 1999-01-12 Basf Aktiengesellschaft Mice transgenic for a tetracycline-controlled transcriptional activator
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US5851796A (en) * 1995-06-07 1998-12-22 Yale University Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
GB9526509D0 (en) * 1995-12-23 1996-02-28 Univ Dundee Gene control
DE19635568C1 (de) * 1996-09-02 1998-03-26 Gsf Forschungszentrum Umwelt Vektorsysteme zur konditionalen Genexpression
WO1998013502A2 (en) * 1996-09-27 1998-04-02 Icos Corporation Method to identify compounds for disrupting protein/protein interactions
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
DE19707493C1 (de) * 1997-02-25 1998-02-26 Univ Ludwigs Albert Nucleinsäurekonstrukte zur lang andauernden Expression von Transgenen
EP0973928B1 (en) 1997-03-11 2010-05-05 Regents Of The University Of Minnesota Dna-based transposon system for the introduction of nucleic acid into dna of a cell
JP2001523103A (ja) 1997-04-28 2001-11-20 ローヌ−プーラン・ロレ・エス・アー 腫瘍治療用血管形成アンタゴニストのアデノウイルスによる腫瘍内送達
US6087166A (en) 1997-07-03 2000-07-11 Basf Aktiengesellschaft Transcriptional activators with graded transactivation potential
WO1999010376A1 (en) * 1997-08-22 1999-03-04 Washington University Inducible regulatory system and use thereof
US5885779A (en) * 1997-09-09 1999-03-23 University Of British Columbia Repressed trans-activator system for characterization of protein-protein interactions
AU9386198A (en) 1997-09-10 1999-03-29 President And Fellows Of Harvard College Inducible methods for repressing gene function
US6673768B1 (en) 1997-10-16 2004-01-06 Board Of Regents, The University Of Texas System Transgenic animal models for cardiac hypertrophy and methods of use thereof (treating)
EP1721986A1 (en) * 1997-10-29 2006-11-15 Genetics Institute, LLC Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
US6136536A (en) * 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
US5968773A (en) * 1997-11-14 1999-10-19 Heddle; John A. System and method for regulation of gene expression
US6331661B1 (en) * 1997-11-18 2001-12-18 Pioneer Hi-Bred International, Inc. Method for directional stable transformation of eukaryotic cells
DE19751587A1 (de) * 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme
US6153383A (en) 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
DE19756975A1 (de) * 1997-12-20 1999-06-24 Hoechst Marion Roussel De Gmbh Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung
CA2316808C (en) 1998-01-08 2007-04-10 Aventis Pharmaceuticals Products Inc. Transgenic rabbit that expresses a functional human lipoprotein (a)
AU2312699A (en) * 1998-01-16 1999-08-02 Pharmacia & Upjohn Company An autoregulatory system for validating microbial genes as possible antimicrobial targets using tetracycline-controllable element
US6878516B1 (en) 1998-01-16 2005-04-12 Pharmacia & Upjohn Company Autoregulatory system for validating microbial genes as possible antimicrobial targets using a tetracycline-controllable element
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
WO2000047754A1 (en) * 1999-02-09 2000-08-17 Rhobio A method for inhibiting the expression of target genes in plants
US6291226B1 (en) 1999-02-25 2001-09-18 National Research Council Of Canada Adenovirus mutants with deleted protease gene
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
WO2000068399A2 (en) * 1999-05-11 2000-11-16 Regents Of The University Of Minnesota Vector-mediated delivery of integrating transposon sequences
CA2369855A1 (en) * 1999-05-28 2001-01-04 Sangamo Biosciences, Inc. Molecular switches
WO2000075347A2 (en) * 1999-06-07 2000-12-14 Wolfgang Hillen Tet repressor-based transcriptional regulatory proteins
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
US6632608B2 (en) 1999-12-30 2003-10-14 President And Fellows Of Harvard College Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
WO2001088192A2 (en) * 2000-05-12 2001-11-22 The Johns Hopkins University A method for generating hypermutable organisms
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
FR2811681A1 (fr) * 2000-07-17 2002-01-18 Commissariat Energie Atomique Procede de criblage de la translocation nucleo-cytoplasmique de proteines sous l'effet d'un stimulus, d'elements y etant impliques et kits de mise en oeuvre
FR2813085A1 (fr) * 2000-08-18 2002-02-22 Aventis Pharma Sa Systeme de regulation in vivo de l'expression d'un transgene par inhibition conditionnelle
JP2004505647A (ja) * 2000-08-18 2004-02-26 ジヤンセル・エス・アー 条件的阻害によるトランスジーンの発現をインビボで調節する方法
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
EP1360310A2 (en) * 2001-02-13 2003-11-12 University Of Florida A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
MXPA03008959A (es) 2001-04-02 2004-10-15 Wyeth Corp Pd-1, un receptor para b7-4 y sus usos.
AU2002257420A1 (en) 2001-05-01 2002-11-11 National Research Council Of Canada A system for inducible expression in eukaryotic cells
US20030221203A1 (en) * 2001-10-03 2003-11-27 Agha-Mohammadi Siamak High efficiency regulatable gene expression system
WO2003054148A2 (en) * 2001-12-07 2003-07-03 University Of Massachusetts Zinc finger-based drug-dependent gene regulation system
EP1497439B1 (de) * 2002-04-15 2006-09-06 Universitätsklinikum Hamburg-Eppendorf Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression
AU2003231048A1 (en) 2002-04-22 2003-11-03 Regents Of The University Of Minnesota Transposon system and methods of use
CA2485939C (en) * 2002-05-29 2013-10-29 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US7666668B2 (en) 2002-08-28 2010-02-23 Tet Systems Holding Gmbh & Co. Kg Chromosomal loci for the stringent control of gene activities via transcription activation systems
FR2845692A1 (fr) * 2002-10-15 2004-04-16 France Hybrides Procede pour produire un mammifere rendu resistant a une infection par un alpha herpes virus par transgenese germinale ainsi que mammifere obtenu par la mise en oeuvre de ce procede
WO2004061077A2 (en) * 2002-12-24 2004-07-22 North Carolina State University Increasing gamete production with a gene switch
US8293503B2 (en) 2003-10-03 2012-10-23 Promega Corporation Vectors for directional cloning
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
JP4838722B2 (ja) 2003-10-24 2011-12-14 ゲンシア コーポレーション ポリヌクレオチドを送達する方法、及び送達用組成物
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US7951532B2 (en) 2003-11-12 2011-05-31 Children's Hospital Medical Center Method of screening a midkine modulating agent
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1935978A4 (en) * 2005-09-15 2009-01-07 Japan Science & Tech Agency PROCESS FOR CONTROLLING PROTEIN REMOVAL BY TETRACYCLIN ANTIBIOTICUM
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
ES2366227T3 (es) * 2005-11-17 2011-10-18 TET Systems GmbH & Co. KG Sistemas de expresión inducibles.
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
HUE037580T2 (hu) 2005-12-09 2018-09-28 Academisch Medisch Centrum Bij De Univ Van Amsterdam Eszközök és eljárások ellenanyag-termelõ sejtek stabilitásának befolyásolására
JP2009537139A (ja) 2006-05-15 2009-10-29 パラテック ファーマシューティカルズ インコーポレイテッド 置換されたテトラサイクリン化合物を用いて、遺伝子または遺伝子産物の発現を制御する方法
US20080300202A1 (en) * 2006-05-18 2008-12-04 The State of Oregon acting by and through the State Board of Higher Education on behalf of the Subtractive transgenics
CN101495633B (zh) 2006-07-28 2015-01-07 塞诺菲-安万特股份有限公司 用于治疗肿瘤的组合物和方法
JPWO2008050774A1 (ja) * 2006-10-23 2010-02-25 大学共同利用機関法人情報・システム研究機構 テトラサイクリン誘導型遺伝子発現細胞株および条件的遺伝子ノックアウト細胞株の製造方法ならびにその用途
US8232099B2 (en) 2007-03-14 2012-07-31 Japan Science And Technology Agency Method for transcription/degradation dual control of protein by antibiotic
US8679845B2 (en) * 2007-05-31 2014-03-25 University Of Washington B cells modified to reversibly induce accelerated mutagenesis of target genes
WO2010037593A1 (en) 2008-10-01 2010-04-08 Tet Systems Holding Gmbh & Co.Kg Tetracycline inducible transcription control sequence
UA106458C2 (uk) 2008-10-28 2014-08-26 Піонер Хай-Бред Інтернешенл, Інк. Чутливий до сульфонілсечовини репресорний білок
US9289475B2 (en) 2008-11-06 2016-03-22 The Johns Hopkins University Treatment of chronic inflammatory respiratory disorders
AU2010271583B2 (en) 2009-07-15 2015-02-12 Kling Biotherapeutics B.V. Means and methods for producing high affinity antibodies
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
EP2366796A1 (en) * 2010-03-09 2011-09-21 Friedrich-Alexander-Universität Erlangen-Nürnberg Means and methods for identifying compounds altering nuclear localization of proteins
WO2011153440A2 (en) 2010-06-04 2011-12-08 Regents Of The University Of Minnesota Transposon mutagenesis system and methods of use
WO2012051301A1 (en) 2010-10-12 2012-04-19 President And Fellows Of Harvard College Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
WO2012071549A2 (en) 2010-11-24 2012-05-31 Clontech Laboratories, Inc. Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same
US9206247B2 (en) 2010-12-02 2015-12-08 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
US9063123B2 (en) 2011-03-29 2015-06-23 Dynavax Technologies Corporation Transgenic mice expressing human toll-like receptor 8
ES2931180T3 (es) 2011-05-19 2022-12-27 Fund Publica Andaluza Progreso Y Salud Sistema de tipo Tet-on lentivírico de promotor dual muy inducible
EP2750715B1 (en) 2011-08-30 2018-10-31 The Regents of The University of California Identification of small molecules that enhance therapeutic exon skipping
JP5871304B2 (ja) * 2011-09-06 2016-03-01 大学共同利用機関法人自然科学研究機構 テトラサイクリン遺伝子発現誘導システムにおける発現量を増幅させる遺伝子座とノックインによる増幅の効果
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
EP3521431A1 (en) 2013-09-25 2019-08-07 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
EP2878674A1 (en) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
EP3099709B1 (en) 2014-01-31 2019-12-25 AIMM Therapeutics B.V. Means and methods for producing stable antibodies
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
WO2017109654A1 (en) * 2015-12-23 2017-06-29 Basf Se Pamamycin controlled systems for gene expression
CN107344962B (zh) * 2016-05-04 2021-03-02 中国科学院微生物研究所 阻遏蛋白、调控元件组和基因表达调控系统及其构建方法
CN108823208B (zh) * 2018-06-29 2021-11-02 中国科学院过程工程研究所 一种四环素诱导启动子及其制备方法和应用
TWI841576B (zh) 2018-07-13 2024-05-11 大陸商南京傳奇生物科技有限公司 用於治療傳染病之共受體系統
AU2019377526A1 (en) 2018-11-08 2021-06-10 Sutro Biopharma, Inc. E coli strains having an oxidative cytoplasm
CN113699147B (zh) 2020-05-22 2023-06-09 深圳市深研生物科技有限公司 基于四环素和Cumate的共调控序列
EP4211156A1 (en) 2020-09-14 2023-07-19 Sutro Biopharma, Inc. Method for large scale production of antibodies using a cell-free protein synthesis system
US11987795B2 (en) 2020-11-24 2024-05-21 The Broad Institute, Inc. Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
WO2022204067A1 (en) 2021-03-24 2022-09-29 Dna Twopointo Inc. Tetracycline-inducible expression systems
US20240207449A1 (en) * 2021-04-09 2024-06-27 Washington University Compositions and methods for treatment of crx-mediated retinopathies
JP2024522112A (ja) 2021-05-27 2024-06-11 中国科学院動物研究所 エンジニアリングされたＣａｓ１２ｉヌクレアーゼ、エフェクタータンパク質及びその用途
CN114085874B (zh) * 2022-01-10 2022-04-29 广东乾晖生物科技有限公司 一种制备肝功能可逆的永生化肝细胞的方法及其应用
WO2024211306A1 (en) 2023-04-03 2024-10-10 Sutro Biopharma, Inc. Rf1 ko e. coli strains
WO2025091009A2 (en) 2023-10-27 2025-05-01 Sutro Biopharma, Inc. Overexpression of lysozyme in t7 rna polymerase-expressing host cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833080A (en) * 1985-12-12 1989-05-23 President And Fellows Of Harvard College Regulation of eucaryotic gene expression
FR2628453B1 (fr) * 1988-03-08 1990-11-16 Cofpa Procede de pose d'une toile autour d'un cylindre et dispositif de pre-tension pour la mise en oeuvre du procede
US5221778A (en) * 1988-08-24 1993-06-22 Yale University Multiplex gene regulation
GB8901676D0 (en) * 1989-01-26 1989-03-15 Ici Plc Regulation of gene expression
JPH04503309A (ja) * 1989-07-28 1992-06-18 アメリカ合衆国 効果的な方向性遺伝子クローニング系
WO1991013979A1 (en) * 1990-03-05 1991-09-19 President And Fellows Of Harvard College Transgenic mouse overexpressing il-4 and method of use
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
CA2084774A1 (en) * 1990-06-12 1991-12-13 Allan Bradley Method for homologous recombination in animal and plant cells
AU8059891A (en) * 1990-06-13 1992-01-07 Trustees Of Princeton University, The A (lac) repressor-hsv vp16 chimeric transcriptional activator protein system functioning in transfected mammalian cells
AU1236092A (en) * 1991-01-04 1992-08-17 Baylor College Of Medicine Tumor susceptible non-human animals
DE4100594A1 (de) * 1991-01-08 1992-07-09 Inst Genbiologische Forschung Neue plasmide zur zeitlichen und oertlichen kontrollierten expression eines heterologen produktes in pflanzen
EP0578653B1 (en) * 1991-03-15 2001-07-18 Hsc Research Development Limited Partnership Gene construct for production of transgenic fish
CA2092695A1 (en) * 1991-05-15 1992-11-16 Oliver Smithies Genomic modifications with homologous dna targeting
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH07509694A (ja) * 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
WO1994004672A1 (en) * 1992-08-26 1994-03-03 Dnx Corp. Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals
CZ206195A3 (en) * 1993-02-12 1996-04-17 Univ Leland Stanford Junior Controlled transcription of target genes and other biological materials
WO1994029442A2 (en) * 1993-06-14 1994-12-22 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters

Also Published As

Publication number Publication date
DE804565T1 (de) 2000-05-04
EP1092771A2 (en) 2001-04-18
CN1523112A (zh) 2004-08-25
CN1167504A (zh) 1997-12-10
US5866755A (en) 1999-02-02
NO315375B1 (no) 2003-08-25
FI965287A7 (fi) 1997-02-28
ATE305034T1 (de) 2005-10-15
DK0804565T3 (da) 2006-02-06
NO965623L (no) 1997-02-28
CA2193122A1 (en) 1996-01-18
DE69534472D1 (de) 2006-02-02
WO1996001313A1 (en) 1996-01-18
FI965287A0 (fi) 1996-12-31
EP1092771A3 (en) 2001-08-01
ES2139552T3 (es) 2006-04-16
AU3092395A (en) 1996-01-25
DE69534472T2 (de) 2006-06-14
EP1092771B1 (en) 2012-12-12
CA2193122C (en) 2005-08-23
JP2008011862A (ja) 2008-01-24
JP2007295938A (ja) 2007-11-15
NO965623D0 (no) 1996-12-30
US20040003417A1 (en) 2004-01-01
JP4054058B2 (ja) 2008-02-27
JP4682176B2 (ja) 2011-05-11
EP0804565A1 (en) 1997-11-05
EP0804565B1 (en) 2005-09-21
JP4820344B2 (ja) 2011-11-24
JPH11506901A (ja) 1999-06-22

Similar Documents

Publication Publication Date Title
ES2139552T1 (es) Moduladores de la transcripcion regulado por tetraciclinas.
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
ATE254664T1 (de) Renilla luciferase und green fluorescent protein fusionsgene
ES2181822T3 (es) Procedimiento para el analisis de expresion de genes.
AR021139A1 (es) Acidos nucleicos y polipeptidos de activadores de la transcripcion y metodos de uso de los mismos
DE3580084D1 (de) Derivat des tryptophan-operons zur expression von verschmolzenen gen-produkten.
DE69329202D1 (de) Methoden der erhöhung der sekretion von überexpremierten proteinen
NO961812D0 (no) Humanproteaseinhibitorer av Kunitz-type
ES2127831T3 (es) Unidades de expresion multicistronicas y su aplicacion.
ES2130803T3 (es) Particulas de celulosa, metodo para su fabricacion y utilizacion de las mismas.
PT1049767E (pt) Coelho transgenico que expressa uma lipoproteina (a) humana funcional
ATE400651T1 (de) Verwendung von grünem fluoreszenzprotein
ES2173314T3 (es) Metodos y composiciones para la modificacion selectiva de acidos nucleicos.
ES2139959T3 (es) Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
ATE286125T1 (de) Regulation der genexpression von bcl-2
NO992116L (no) Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
ES2058599T3 (es) Procedimiento para mejorar la eficacia de las toxinas de insectos.
ATE168136T1 (de) Nichtradioaktive dns-sequenzierung
DE69824839D1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5-halogen-pyridinen, verwendbar als cox-2 inhibitoren
ATE243741T1 (de) Zufuhr von genprodukten mittels mesangium-zellen
AR009819A1 (es) Inhibidores de la proteasa proteinicos estabilizados y sus variantes
MX9701295A (es) Metodos para identificar compuestos utiles para el tratamiento de enfermedades autoinmunes.
ATE389727T1 (de) Modulatoren der expression von morphogenen und deren identifizierungsverfahren
SE9603344D0 (sv) Method and apparatus for detecting substances